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Background: Previous studies have shown the effectiveness of everolimus-eluting stent (EES) for small-vessel disease. However, the impact of 
biolimus-eluting stent (BES) on clinical outcome in patients with small-vessel disease remains unclear. The aim of this study was to compare clinical 
outcome between BES and EES in patients with small-vessel disease.
methods: A total of 929 patients treated with only BES (485 patients with 534 lesions) or EES (444 patients with 515 lesions) in small-vessel 
lesions (stent size 2.5 mm) were retrospectively analyzed. The study endpoints were major adverse cardiovascular events (MACE) defined as a 
composite of cardiac death, myocardial infarction (MI), clinical driven target lesion revascularization (CDTLR) and definite stent thrombosis at 
1-year.
results: The baseline characteristics were similar between the BES and EES groups except for the prevalence of hemodialysis and previous MI. 
At 1-year, the incidence of MACE was similar between the 2 groups (3.2% vs. 4.7%, P=0.27). Cumulative incidence of MI, CDTLR, and definite stent 
thrombosis were not significantly different between the 2 groups (0.002% vs. 0.0%, P=0.35; 3.2% vs. 4.7%, P=0.27; 0.002% vs. 0.0%, P=0.35, 
respectively)
conclusions: One-year clinical outcome of BES was similar to that of EES in patients with small-vessel disease, despite the difference in stent strut 
thickness between BES and EES. The use of BES is effective for small coronary artery disease.
